 SAN DIEGO--BUSINESS WIRE--Janux Therapeutics, Inc. Nasdaq: JANX Janux, a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager TRACTr and Tumor Activated Immunomodulator TRACIr platforms, today announced that Janux management will present at the virtual H.C. Wainwright 23rd Annual Global Investor Conference being held September 13 to 15, 2021. The corporate presentation will be availa 